Table Info

Table 1.

Advantages and disadvantages of different tissue dissociation methods

Tissue dissociation methods	Advantages	Disadvantages
Enzymatic [8–10]	-Extraction of a sufficient quantity of required cells. -Accessibility and widespread application. -Relatively easy removal of stromal cells and fibroblasts.	Requires the selection of specific enzymes for each type of tumor tissue.
Chemical [11, 12]	-Allows better preservation of phenotypic and genetic characteristics. -Cells divide rapidly when cultivated.	The complexity of the procedure, with the efficiency not fully established.
Mechanic [8–13]	Simplicity and accessibility, with no chemical impact on cells.	-Formation of a large number of non-viable cells. -Release of cell contents with damaged membranes into the external environment, and sample contamination.

Declarations

Author contributions

VVP: Writing—original draft, Writing—review & editing. ZEG, SSI, AAR, and VVS: Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This paper has been supported by the Russian Science Foundation grant [21-74-10021]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Mingaleeva RN, Solovieva VV, Blatt NL, Rizvanov AA. Application of cell and tissue cultures for potential anti-cancer/oncology drugs screening in vitro. Genes & Cells. 2013;8:20–8. Russian. [DOI]

Kitaeva KV, Rizvanov AA, Solovyeva VV. Modern methods of preclinical anticancer drug screening using test systems based on cell cultures. Uch Zap Kazan Univ Ser Estestv Nauki. 2021;163:155–76. Russian. [DOI]

Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Cell culture based in vitro test systems for anticancer drug screening. Front Bioeng Biotechnol. 2020;8:322. [DOI] [PubMed] [PMC]

Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011;29:1916–23. [DOI] [PubMed]

Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013;31:347–54. [DOI] [PubMed] [PMC]

Meditz K, Rinner B. Establishment of of tumor cell lines: from primary tumor cells to a tumor cell line. In: Kasper C, Charwat V, Lavrentieva A, editors. Cell Culture Technology. Cham: Springer International Publishing; 2018. pp. 61–73.

Torzilli G, Procopio F, Palmisano A, Donadon M, Del Fabbro D, Marconi M, et al. Total or partial anatomical resection of segment 8 using the ultrasound-guided finger compression technique. HPB (Oxford). 2011;13:586–91. [DOI] [PubMed] [PMC]

Ljung BM, Mayall B, Lottich C, Boyer C, Sylvester SS, Leight GS, et al. Cell dissociation techniques in human breast cancer—variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat. 1989;13:153–9. [DOI] [PubMed]

Mitaka T. The current status of primary hepatocyte culture. Int J Exp Pathol. 1998;79:393–409. [DOI] [PubMed] [PMC]

10.

Li WC, Ralphs KL, Tosh D. Isolation and culture of adult mouse hepatocytes. Methods Mol Biol. 2010;633:185–96. [DOI] [PubMed]

11.

Castell JV, Gómez-Lechón MJ. Liver cell culture techniques. Methods Mol Biol. 2009;481:35–46. [DOI] [PubMed]

12.

Harris CC, Leone CA. Some effects of EDTA and tetraphenylboron on the ultrastructure of mitochondria in mouse liver cells. J Cell Biol. 1966;28:405–8. [DOI] [PubMed] [PMC]

13.

Cunningham RE. Tissue disaggregation. Methods Mol Biol. 2010;588:327–30. [DOI] [PubMed]

14.

Ayabe T, Shimizu TM, Tomita M, Yano M, Nakamura K, Onitsuka T. Emergent completion pneumonectomy for postoperative hemorrhage from rupture of the infected pulmonary artery in lung cancer surgery. Case Rep Surg. 2011;2011:902062. [DOI] [PubMed] [PMC]

15.

Mitra R, Morad M. A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am J Physiol. 1985;249:H1056-1060. [DOI] [PubMed]

16.

Janik K, Popeda M, Peciak J, Rosiak K, Smolarz M, Treda C, et al. Efficient and simple approach to in vitro culture of primary epithelial cancer cells. Biosci Rep. 2016;36:e00423. [DOI] [PubMed] [PMC]

17.

Singh R, Bandyopadhyay D. MUC1: A target molecule for cancer therapy. Cancer Biol Ther. 2007;6:481–6. [DOI] [PubMed]

18.

Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, et al. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer. 1997;71:741–9. [DOI] [PubMed]

19.

Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. 1996;56:860–5. [PubMed]

20.

Wu K, Weng Z, Tao Q, Lin G, Wu X, Qian H, et al. Stage-specific expression of breast cancer-specific gene gamma-synuclein. Cancer Epidemiol Biomarkers Prev. 2003;12:920–5. [PubMed]

21.

Daigeler A, Klein-Hitpass L, Chromik AM, Müller O, Hauser J, Homann HH, et al. Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer. 2008;8:313. [DOI] [PubMed] [PMC]

22.

Lobo NC, Gedye C, Apostoli AJ, Brown KR, Paterson J, Stickle N, et al. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine. BMC Cancer. 2016;16:485. [DOI] [PubMed] [PMC]

23.

Stoczynska-Fidelus E, Piaskowski S, Bienkowski M, Banaszczyk M, Hulas-Bigoszewska K, Winiecka-Klimek M, et al. The failure in the stabilization of glioblastoma-derived cell lines: spontaneous in vitro senescence as the main culprit. PLoS One. 2014;9:e87136. [DOI] [PubMed] [PMC]

24.

Piwocka O, Musielak M, Ampuła K, Piotrowski I, Adamczyk B, Fundowicz M, et al. Navigating challenges: optimising methods for primary cell culture isolation. Cancer Cell Int. 2024;24:28. [DOI] [PubMed] [PMC]

25.

Ozaslan M, Karagoz I, Kılıç İ, Guldur M. Ehrlich ascites carcinoma. Afr J Biotechnol. 2011;10:2375–8.

26.

Abreu TR, Biscaia M, Gonçalves N, Fonseca NA, Moreira JN. In vitro and in vivo tumor models for the evaluation of anticancer nanoparticles. Adv Exp Med Biol. 2021;1295:271–99. [DOI] [PubMed]

27.

Guo D, Zhang L, Wang X, Zheng J, Lin S. Establishment methods and research progress of livestock and poultry immortalized cell lines: A review. Front Vet Sci. 2022;9:956357. [DOI] [PubMed] [PMC]

28.

Abercrombie M, Ambrose EJ. Interference microscope studies of cell contacts in tissue culture. Exp Cell Res. 1958;15:332–45. [DOI] [PubMed]

29.

Paul J. The cancer cell in vitro: a review. Cancer Res. 1962;22:431–40. [PubMed]

30.

Sanford KK, Barker BE, Woods MW, Parshad R, Law LW. Search for “indicators” of neoplastic conversion in vitro. J Natl Cancer Inst. 1967;39:705–33. [PubMed]

31.

Hudson EA, Fox LH, Luckett JCA, Manson MM. Ex vivo cancer chemoprevention research possibilities. Environ Toxicol Pharmacol. 2006;21:204–14. [DOI] [PubMed]

32.

Wu X, Wang S, Li M, Li J, Shen J, Zhao Y, et al. Conditional reprogramming: next generation cell culture. Acta Pharmaceutica Sinica B. 2020;10:1360–81. [DOI] [PubMed] [PMC]

33.

Bartek J, Bartkova J, Kyprianou N, Lalani EN, Staskova Z, Shearer M, et al. Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci USA. 1991;88:3520–4. [DOI] [PubMed] [PMC]

34.

Taylor-Papadimitriou J, Shearer M, Stoker MGP. Growth requirements of human mammary epithelial cells in culture. Int J Cancer. 1977;20:903–8. [DOI] [PubMed]

35.

Claassen DA, Desler MM, Rizzino A. ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. Mol Reprod Dev. 2009;76:722–32. [DOI] [PubMed] [PMC]

36.

Liu P, Bian Y, Zhong J, Yang Y, Mu X, Liu Z. Establishment and characterization of a rat intestinal microvascular endothelial cell line. Tissue and Cell. 2021;72:101573. [DOI] [PubMed]

37.

Scarth JA, Patterson MR, Morgan EL, Macdonald A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol. 2021;102:001540. [DOI] [PubMed] [PMC]

38.

Van Doorslaer K, Burk RD. Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology. 2012;433:216–9. [DOI] [PubMed] [PMC]

39.

Manfredi J, Prives C. The transforming activity of simian virus 40 large tumor antigen. Biochim Biophys Acta. 1994;1198:65–83. [DOI] [PubMed]

40.

Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75:495–505. [DOI] [PubMed]

41.

Peta E, Sinigaglia A, Masi G, Di Camillo B, Grassi A, Trevisan M, et al. HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys. Oncogene. 2018;37:1654–68. [DOI] [PubMed]

42.

Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56:4620–4. [PubMed]

43.

Greider CW. Telomere length regulation. Annu Rev Biochem. 1996;65:337–65. [DOI] [PubMed]

44.

Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev. 1998;12:1769–74. [DOI] [PubMed] [PMC]

45.

Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest. 2010;120:2619–26. [DOI] [PubMed] [PMC]

46.

Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, et al. Management and potentialities of primary cancer cultures in preclinical and translational studies. J Transl Med. 2017;15:229. [DOI] [PubMed] [PMC]

47.

Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol. 2013;10:483–7. [DOI] [PubMed]

48.

Masters JRW. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol. 2000;1:233–6. [DOI] [PubMed]

49.

Drexler H, Fombonne S, Matsuo Y, Hu ZB, Hamaguchi H, Uphoff C. p53 alterations in human leukemia–lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization? Leukemia. 2000;14:198–206. [DOI] [PubMed]

50.

Hartmann C, Kluwe L, Lücke M, Westphal M. The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors. Int J Oncol. 1999;15:975–1057. [DOI] [PubMed]

51.

Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 1999;5:991–1000. [PubMed]

52.

Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11:2756–61. [DOI] [PubMed] [PMC]

53.

Vannucci L. Stroma as an active player in the development of the tumor microenvironment. Cancer Microenviron. 2015;8:159–66. [DOI] [PubMed] [PMC]

54.

Nelson SR, Walsh N. Genetic alterations featuring biological models to tailor clinical management of pancreatic cancer patients. Cancers. 2020;12:1233. [DOI] [PubMed] [PMC]

55.

Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325–30. [DOI] [PubMed] [PMC]

56.

Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer. 2010;68:309–18. [DOI] [PubMed] [PMC]

57.

Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA. 2011;108:18708–13. [DOI] [PubMed] [PMC]

58.

Qiu Z, Zou K, Zhuang L, Qin J, Li H, Li C, et al. Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Sci Rep. 2016;6:27411. [DOI] [PubMed] [PMC]

59.

Esparza-López J, Martínez-Aguilar JF, Ibarra-Sánchez MDJ. Deriving primary cancer cell cultures for personalized therapy. RIC. 2019;71:369–80. [DOI] [PubMed]

60.

Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010;10:375–9. [DOI] [PubMed]

61.

Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis. 2012;2:1–5. [DOI] [PubMed] [PMC]

62.

Lee J, Hwang J, Kim HS, Kim S, Kim YH, Park SY, et al. A comparison of gene expression profiles between primary human AML cells and AML cell line. Genes Genet Syst. 2008;83:339–45. [DOI] [PubMed]

63.

Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. A molecular “signature” of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics. 2004;5:47. [DOI] [PubMed] [PMC]

64.

Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis. 2005;8:197–204. [DOI] [PubMed]

65.

Niu N, Wang L. In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics. 2015;16:273–85. [DOI] [PubMed] [PMC]

66.

Falasca M, Raimondi C, Maffucci T. Boyden chamber. Methods Mol Biol. 2011;769:87–95. [DOI] [PubMed]

67.

Chowdhury AN, Vo HT, Olang S, Mappus E, Peterson B, Hlavac N, et al. A customizable chamber for measuring cell migration. J Vis Exp. 2017;121:55264. [DOI] [PubMed] [PMC]

68.

Nelson PR, Yamamura S, Kent KC. Platelet-derived growth factor and extracellular matrix proteins provide a synergistic stimulus for human vascular smooth muscle cell migration. J Vasc Surg. 1997;26:104–12. [DOI] [PubMed]

69.

Richbart SD, Merritt JC, Moles EG, Brown KC, Adeluola AA, Finch PT, et al. Spherical invasion assay: a novel method to measure invasion of cancer cells. Bio Protoc. 2022;12:e4320. [DOI] [PubMed] [PMC]

70.

Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol. 2011;740:33–43. [DOI] [PubMed]

71.

Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012;7:e46536. [DOI] [PubMed] [PMC]

72.

Marshall J. Transwell(®) invasion assays. Methods Mol Biol. 2011;769:97–110. [DOI] [PubMed]

73.

Bouchalova P, Bouchal P. Current methods for studying metastatic potential of tumor cells. Cancer Cell Int. 2022;22:394. [DOI] [PubMed] [PMC]

74.

Park M, Bang C, Yun WS, Jin S, Jeong YM. Transwell-hypoxia method facilitates the outgrowth of 3d-printed collagen scaffolds loaded with cryopreserved patient-derived melanoma explants. ACS Appl Bio Mater. 2022;5:5302–9. [DOI] [PubMed] [PMC]

75.

Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K. Tumor‐derived spheroids: relevance to cancer stem cells and clinical applications. Cancer Sci. 2017;108:283–9. [DOI] [PubMed] [PMC]

76.

Han SJ, Kwon S, Kim KS. Challenges of applying multicellular tumor spheroids in preclinical phase. Cancer Cell Int. 2021;21:152. [DOI] [PubMed] [PMC]

77.

Durand RE, Olive PL. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. In: Methods in Cell Biology. Elsevier; 2001. p. 211–33. [DOI] [PubMed]

78.

Rajcevic U, Knol JC, Piersma S, Bougnaud S, Fack F, Sundlisaeter E, et al. Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. Proteome Sci. 2014;12:39. [DOI] [PubMed] [PMC]

79.

Melissaridou S, Wiechec E, Magan M, Jain MV, Chung MK, Farnebo L, et al. The effect of 2D and 3D cell cultures on treatment response, EMT profile and stem cell features in head and neck cancer. Cancer Cell Int. 2019;19:16. [DOI] [PubMed] [PMC]

80.

Clevers H. Modeling development and disease with organoids. Cell. 2016;165:1586–97. [DOI] [PubMed]

81.

Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, et al. Human primary liver cancer–derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23:1424–35. [DOI] [PubMed] [PMC]

82.

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172:373–86.e10. [DOI] [PubMed]

83.

Brennan M, Lim B. The actual role of receptors as cancer markers, biochemical and clinical aspects: receptors in breast cancer. Adv Exp Med Biol. 2015;867:327–37. [DOI] [PubMed]

84.

Kanton S, Paşca SP. Human assembloids. Development. 2022;149:dev201120. [DOI] [PubMed]

85.

Pașca SP, Arlotta P, Bateup HS, Camp JG, Cappello S, Gage FH, et al. A nomenclature consensus for nervous system organoids and assembloids. Nature. 2022;609:907–10. [DOI] [PubMed] [PMC]

86.

Lv Q, Wang Y, Xiong Z, Xue Y, Li J, Chen M, et al. Microvascularized tumor assembloids model for drug delivery evaluation in colorectal cancer-derived peritoneal metastasis. Acta Biomaterialia. 2023;168:346–60. [DOI] [PubMed]

87.

Kim E, Choi S, Kang B, Kong J, Kim Y, Yoon WH, et al. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature. 2020;588:664–9. [DOI] [PubMed]

88.

Sharpe BP, Nazlamova LA, Tse C, Johnston DA, Blyth R, Pickering OJ, et al. Patient- derived tumor organoid and fibroblast assembloid models for interrogation of the tumor microenvironment in esophageal adenocarcinoma. BioRxiv [Preprint]. 2024 [cited 2024 Jan 02]. Available from: https://www.biorxiv.org/content/10.1101/2024.01.02.572565v2.full.pdf

89.

Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13:4. [DOI] [PubMed] [PMC]

90.

Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Mouse tumor models for advanced cancer immunotherapy. Int J Mol Sci. 2020;21:4118. [DOI] [PubMed] [PMC]

91.

Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun. 2015;6:8305. [DOI] [PubMed] [PMC]

92.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, et al. A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors. Clin Cancer Res. 2017;23:6468–77. [DOI] [PubMed] [PMC]

93.

Mosmann TR, Yokota T, Kastelein R, Zurawski SM, Arai N, Takebe Y. Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J Immunol. 1987;138:1813–6. [PubMed]

94.

DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MTW, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514–20. [DOI] [PubMed] [PMC]

95.

Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526:131–5. [DOI] [PubMed] [PMC]

96.

Monjezi M, Rismanian M, Jamaati H, Kashaninejad N. Anti- cancer drug screening with microfluidic technology. Appl Sci. 2021;11:9418. [DOI]

97.

Anguiano M, Castilla C, Maška M, Ederra C, Peláez R, Morales X, et al. Characterization of three-dimensional cancer cell migration in mixed collagen-Matrigel scaffolds using microfluidics and image analysis. PLoS One. 2017;12:e0171417. [DOI] [PubMed] [PMC]

98.

Patra B, Peng CC, Liao WH, Lee CH, Tung YC. Drug testing and flow cytometry analysis on a large number of uniform sized tumor spheroids using a microfluidic device. Sci Rep. 2016;6:21061. [DOI] [PubMed] [PMC]

99.

Lim W, Park S. A microfluidic spheroid culture device with a concentration gradient generator for high-throughput screening of drug efficacy. Molecules. 2018;23:3355. [DOI] [PubMed] [PMC]

100.

Shirure VS, Bi Y, Curtis MB, Lezia A, Goedegebuure MM, Goedegebuure SP, et al. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids. Lab Chip. 2018;18:3687–702. [DOI] [PubMed] [PMC]

101.

Han S, Kim S, Chen Z, Shin HK, Lee SY, Moon HE, et al. 3D bioprinted vascularized tumour for drug testing. Int J Mol Sci. 2020;21:2993. [DOI] [PubMed] [PMC]